Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AC Immune SA stock logo
ACIU
AC Immune
$1.69
$1.68
$1.43
$4.98
$169.69M1.62167,437 shs130,042 shs
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
$7.49
+4.9%
$6.66
$5.01
$18.71
$44.65M0.3124,517 shs63,502 shs
INmune Bio, Inc. stock logo
INMB
INmune Bio
$7.65
+4.8%
$7.58
$4.32
$10.50
$175.83M1.63261,458 shs301,352 shs
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
$1.27
-1.6%
$1.49
$1.11
$8.14
$166.74M1.91.32 million shs1.64 million shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AC Immune SA stock logo
ACIU
AC Immune
0.00%-3.43%+3.05%-32.94%-52.26%
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
+4.90%+7.00%+2.32%+1.35%-51.99%
INmune Bio, Inc. stock logo
INMB
INmune Bio
+4.79%-0.39%-2.17%-1.92%-24.33%
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
-1.55%+8.09%-24.85%-50.00%-81.67%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AC Immune SA stock logo
ACIU
AC Immune
2.6085 of 5 stars
3.53.00.00.02.40.81.3
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
4.1631 of 5 stars
3.33.00.04.72.42.50.6
INmune Bio, Inc. stock logo
INMB
INmune Bio
1.3527 of 5 stars
3.61.00.00.00.01.70.6
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
3.6841 of 5 stars
4.40.00.00.02.33.31.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AC Immune SA stock logo
ACIU
AC Immune
3.00
Buy$10.00491.72% Upside
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
2.57
Moderate Buy$17.75136.98% Upside
INmune Bio, Inc. stock logo
INMB
INmune Bio
3.17
Buy$22.80198.04% Upside
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
2.75
Moderate Buy$10.08693.96% Upside

Current Analyst Ratings Breakdown

Latest ATRA, ACIU, PRME, and INMB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/27/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$10.00 ➝ $1.50
5/20/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $6.00
5/20/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
5/20/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Neutral
5/19/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $12.00
5/1/2025
AC Immune SA stock logo
ACIU
AC Immune
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $12.00
4/3/2025
AC Immune SA stock logo
ACIU
AC Immune
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
3/20/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $16.00
3/19/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
3/18/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$12.00 ➝ $13.00
3/14/2025
AC Immune SA stock logo
ACIU
AC Immune
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AC Immune SA stock logo
ACIU
AC Immune
$28.30M6.00N/AN/A$2.12 per share0.80
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
$199.73M0.22N/AN/A($24.34) per share-0.31
INmune Bio, Inc. stock logo
INMB
INmune Bio
$50K3,516.55N/AN/A$2.07 per share3.70
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
$3.85M43.36N/AN/A$1.37 per share0.93
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AC Immune SA stock logo
ACIU
AC Immune
-$60.41M-$0.58N/AN/AN/AN/A-28.26%-18.98%8/5/2025 (Estimated)
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
-$276.13M-$3.72N/AN/AN/A-132.58%N/A-90.16%8/11/2025 (Estimated)
INmune Bio, Inc. stock logo
INMB
INmune Bio
-$30.01M-$1.93N/AN/AN/AN/A-117.48%-78.96%8/7/2025 (Estimated)
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
-$198.13M-$1.61N/AN/AN/AN/A-107.87%-74.97%N/A

Latest ATRA, ACIU, PRME, and INMB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
-$3.07$3.50+$6.57$3.50$4.30 million$98.10 million
5/8/2025Q1 2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
-$0.43-$0.43N/A-$0.43N/A$0.05 million
4/30/2025Q1 2025
AC Immune SA stock logo
ACIU
AC Immune
-$0.22-$0.21+$0.01-$0.21$1.99 million$1.12 million
3/27/2025Q4 2024
INmune Bio, Inc. stock logo
INMB
INmune Bio
-$0.54-$0.40+$0.14-$0.40N/AN/A
3/7/2025Q4 2024
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
-$3.82-$1.19+$2.63-$1.19$20.58 million$32.75 million
3/7/2025Full Year
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
N/A-$1.65N/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AC Immune SA stock logo
ACIU
AC Immune
N/AN/AN/AN/AN/A
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
N/AN/AN/AN/AN/A
INmune Bio, Inc. stock logo
INMB
INmune Bio
N/AN/AN/AN/AN/A
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
$1.45113.86%N/AN/A N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AC Immune SA stock logo
ACIU
AC Immune
N/A
1.86
1.86
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
N/A
0.59
0.50
INmune Bio, Inc. stock logo
INMB
INmune Bio
N/A
2.59
2.59
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
N/A
6.50
6.50

Institutional Ownership

CompanyInstitutional Ownership
AC Immune SA stock logo
ACIU
AC Immune
51.36%
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
70.90%
INmune Bio, Inc. stock logo
INMB
INmune Bio
12.72%
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
70.37%

Insider Ownership

CompanyInsider Ownership
AC Immune SA stock logo
ACIU
AC Immune
4.60%
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
3.70%
INmune Bio, Inc. stock logo
INMB
INmune Bio
35.20%
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
23.47%
CompanyEmployeesShares OutstandingFree FloatOptionable
AC Immune SA stock logo
ACIU
AC Immune
140100.41 million94.39 millionOptionable
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
3305.96 million5.55 millionOptionable
INmune Bio, Inc. stock logo
INMB
INmune Bio
1022.98 million14.37 millionOptionable
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
234131.29 million100.38 millionOptionable

Recent News About These Companies

Citigroup Downgrades Prime Medicine (PRME)
Prime Medicine (NYSE:PRME) Earns Neutral Rating from Citigroup
FY2025 EPS Estimates for Prime Medicine Increased by Analyst
Prime Medicine FY2029 EPS Forecast Lowered by HC Wainwright
What is Wedbush's Estimate for Prime Medicine Q3 Earnings?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AC Immune stock logo

AC Immune NASDAQ:ACIU

$1.69 0.00 (0.00%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$1.72 +0.04 (+2.07%)
As of 05/27/2025 05:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Atara Biotherapeutics stock logo

Atara Biotherapeutics NASDAQ:ATRA

$7.49 +0.35 (+4.90%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$7.45 -0.04 (-0.48%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

INmune Bio stock logo

INmune Bio NASDAQ:INMB

$7.65 +0.35 (+4.79%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$7.73 +0.08 (+1.03%)
As of 06:43 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Prime Medicine stock logo

Prime Medicine NYSE:PRME

$1.27 -0.02 (-1.55%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$1.28 +0.01 (+0.79%)
As of 08:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.